Abstract: Ovarian serous borderline tumors (SBTs) have been the subject of considerable controversy, particularly with regard to terminology and behavior. It has been proposed that they constitute a heterogenous group of tumors composed, for the most part, of typical SBTs that are benign and designated "atypical proliferative serous tumor (APST)" and a small subset of SBTs with micropapillary architecture that have a poor outcome and are designated "noninvasive low-grade serous carcinoma (niLGSC)". It also has been argued that the difference in behavior between the 2 groups is not due to the subtype of the primary tumor but rather the presence of extraovarian disease, specifically invasive implants. According to the terminology of the 2014 WHO Classification, typical SBTs are equivalent to APSTs and SBTs displaying micropapillary architecture are synonymous with niLGSC. In addition, "invasive implants" were renamed "low-grade serous carcinoma" (LGSC). The argument as to whether it is the appearance of the primary tumor or the presence of extraovarian LGSC that determines outcome remains unsettled. The current study was initiated in 2004 and was designed to determine what factors were predictive of outcome, with special attention to the appearance of the primary tumor (APST vs. niLGSC) and that of the extraovarian disease (noninvasive vs. invasive implants). Our study is population based, involving the entire female population of Denmark. None of the women in the study were lost to follow-up, which ranged up to 36 years (median, 15 y). All the microscopic slides from the contributing hospitals were rereviewed by a panel of 2 pathologists (R.V. and R.J.K.) who were blinded to the follow-up. After excluding those that were not SBTs by the pathology panel, as well as cases with a prior or concurrent cancer or undefined stage, 942 women remained, of which 867 were APSTs and 75 were niLGSCs. The median patient age was 50 years (range, 16 to 97 y). Eight hundred nine women (86%) presented with FIGO stage I disease, whereas 133 (14%) had advanced stage disease. Compared with APSTs, niLGSC exhibited a significantly greater frequency of bilaterality, residual gross disease after surgery, microinvasion/ microinvasive carcinoma, advanced stage disease, and invasive implants at presentation (P-values <0.003). Because the cause of death is difficult to accurately ascertain from death certificates, we used development of invasive serous carcinoma as the primary endpoint as following development of carcinoma, the mortality is very high. In the entire cohort, subsequent development of carcinoma occurred in 4%, of which 93% were low grade and 7% high grade (median time, 10 y; range, up to 25 y). After adjusting for age at and time since diagnosis of APST or niLGSC, occurrence of subsequent carcinoma was significantly higher with niLGSC than APST among all stages combined (hazard ratio [HR] = 3.8; 95% confidence interval [CI], 1.7-8.2). This difference was still significant for stage I but not advanced stage cases. Moreover, all-cause mortality was not statistically significantly different between APST and niLGSC. Of all women with advanced stage disease, 114 (86%) had noninvasive implants, whereas 19 (14%) were invasive. Noninvasive implants were significantly associated with subsequent development of carcinoma (HR = 7.7; 95% CI, 3.9-15.0), but the risk with invasive implants was significantly higher (HR = 42.3; 95% CI, 16.1-111.1). In conclusion, although invasive implants are the most important feature in predicting an adverse outcome, subclassification into APST and niLGSC is important as it stratifies women with respect to risk for advanced stage disease and invasive implants for all women and development of serous carcinoma for stage I cases.
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S
ince the establishment of ovarian serous borderline tumors (SBTs) as a distinct group in the FIGO and WHO ovarian tumor classifications in the early 1970s, there have been significant advances in our understanding of these neoplasms. [1] [2] [3] [4] [5] [6] [7] [8] One was that invasive implants were a very important factor in predicting adverse outcome and another that SBTs with a micropapillary or cribriform pattern were more frequently associated with invasive implants and aggressive behavior. 9, 10 The latter finding led to the proposal that the typical SBTs were benign and that micropapillary SBTs were a noninvasive low-grade serous carcinoma (niLGSC). Accordingly, it was proposed that the former tumor be designated "atypical proliferative serous tumor (APST)" and the latter "noninvasive low-grade serous carcinoma", which offered an apparent explanation for the "low malignant potential" behavior of this entire group of tumors. Subsequently, a number of studies comparing the clinicopathologic features of typical SBT and the micropapillary variant were performed yielding different results. This led to considerable debate [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] as it was argued that the poor prognosis associated with the niLGSC was not due to the appearance of the ovarian neoplasm but was due to the associated invasive implants. According to the terminology of the 2014 WHO Classification, typical SBTs are equivalent to APSTs and SBTs displaying micropapillary architecture are synonymous with niLGSC. 5 In addition, "invasive implants" were renamed "low-grade serous carcinoma (LGSC)." The argument as to whether it is the appearance of the primary tumor or the presence of extraovarian LGSC that dictated outcome remains unsettled.
Reviews of the literature 6,22 drew attention to a variety of limitations in the previously published studies of SBTs that compromised an accurate understanding of their behavior. These usually included relatively small numbers of cases (< 200 cases), relatively short follow-up (r8 y), a substantial number of patients lost to follow-up, and selection bias as virtually all investigations were from tertiary care institutions. Lastly, the small number of populationbased studies either lacked pathology rereview or had relatively small numbers of patients or short follow-up. [23] [24] [25] [26] [27] [28] [29] In an effort to address these issues, we conducted a large population-based study of noninvasive low-grade serous tumors involving the entire female population of Denmark including pathology rereview and long-term follow-up, with no losses to follow-up. The main aim of the current study was to describe the clinicopathologic features of APSTs and niLGSCs, as well as implants and microinvasion/microinvasive carcinoma, and to assess the behavioral differences between APSTs and niLGSCs and noninvasive and invasive implants, where women with a history of cancer (ovarian or nonovarian sites except for nonmelanoma skin cancers) have been excluded.
MATERIALS AND METHODS

Study Population
The study was approved by the Danish Data Protection Agency and the Danish Scientific Ethical Committee.
The complete epidemiologic characteristics and details of study design of this Danish cohort have been previously reported. 30 Briefly, all cases with a file diagnosis of SBT during 1978 to 2002 were identified in the Danish Pathology Data Bank and/or Danish Cancer Registry, which are nationwide registries. Of 1487 such cases, slides were retrieved for 1259, and after rereview of H&E slides, 265 cases were excluded as not being an SBT. Of these, 237 were serous cystadenoma/adenofibroma with minute/focal epithelial proliferation, 12 were borderline tumors of non-serous type, and 16 were invasive carcinomas of various types. To detect SBTs misclassified as carcinoma, cases with a file diagnosis of well-differentiated serous carcinoma from 1997 to 2002 were identified, and of the 107 such cases, 48 were interpreted as SBT after rereview. In summary, 1042 cases from all searched registries were considered SBT after rereview. In all analyses, we excluded women with a history of cancer (ovarian or nonovarian sites except for nonmelanoma skin cancers) before or concurrent with the diagnosis of SBT, as well as women with undefined stage of SBT, leaving 942 women with a confirmed diagnosis of SBT for analysis in the present study.
Pathology Rereview
All H&E slides from the primary ovarian tumor and nonovarian sites were obtained from the various pathology departments in Denmark. Slides from all cases were reviewed by 2 of the authors (R.V. and R.J.K.) who were blinded to all clinical parameters. The SBTs were classified according to the criteria of the National Cancer Institute's Borderline Ovarian Tumor Workshop in 2003 7 and 2014 WHO. 5 An SBT was defined as a noninvasive low-grade serous tumor with intracystic or exophytic growth, with papillary architecture and papillae lined by stratified epithelium, and displaying greater architectural proliferation than a cystadenoma/adenofibroma but lacking destructive stromal invasion of invasive carcinoma. A diagnosis required at least 10% epithelial proliferation of the tumor for the distinction from papillary forms of serous cystadenoma/adenofibroma.
Neoplasms were subclassified as APST or niLGSC. Tumors with foci of micropapillary growth measuring Z5 mm in greatest dimension were classified as niLGSC, whereas tumors with no micropapillary foci or foci of micropapillary growth measuring <5 mm in greatest dimension were classified as APST. It is important to emphasize that in making the diagnosis of a niLGSC, the cytologic features should be considered. Unlike APSTs that are composed of a heterogenous population of cuboidal, columnar, ciliated, and rounded cells with abundant eosinophilic cytoplasm containing bland nuclei, the cells in niLGSC are relatively uniform in appearance, with a higher nuclear:cytoplasmic ratio, coarser nuclear chromatin, and frequently small but prominent nucleoli. They closely resemble invasive LGSC. Furthermore, they lack the eosinophilic cells and ciliated cells that are so conspicuous in APSTs.
Implants were classified as noninvasive (epithelial or desmoplastic type) or invasive based on traditional (tissue invasion) 1 or expanded criteria. 3 The latter were used when there were implants showing micropapillary or cribriform/confluent patterns similar to niLGSC, and/or solid nests surrounded by a clear space, but in which there was no obvious infiltration into normal underlying tissue. For purposes of this study, cases meeting either traditional or expanded criteria were classified as invasive implants.
As the threshold for distinguishing the upper size limit of "microinvasion" from the lower limit of invasive LGSC varies in different studies and as no scientifically validated measurement has been established, no specific size cutoff was used in this study as long as the foci in question did not exhibit destructive stromal invasion as defined elsewhere. 31 Thus, patterns of stromal invasion not showing destructive stromal invasion were included regardless of the size or number of foci. The greatest linear dimension for the largest single focus in any case was classified as <3 mm, Z3 to <5 mm, or Z5 mm.
The 2014 WHO Classification for Gynecologic Tumors describes 2 types of "microinvasion." 5 The more common pattern is the conventional type, which frequently contains single cells, small clusters of cells, and small papillae within stroma, which is termed "microinvasion." The other less common type features a micropapillary pattern, which in addition to micropapillae, often contains small solid nests of cells surrounded by a clear space or cleft within the stroma, as well as inverted macropapillary and cribriform patterns, and is designated "microinvasive carcinoma" as it resembles invasive LGSC. In this study, cases were classified as having either only the conventional type of microinvasion or microinvasive carcinoma (regardless of the coexisting presence of the conventional type of microinvasion).
Surgical Procedures and Staging
Hospitals in which the study patients were admitted for surgery and subsequent treatment were identified by linkage with the National Patient Registry in Denmark. All medical records were reviewed, and data were extracted. All women were treated according to the Danish clinical guidelines for ovarian borderline tumors/cancer, which previously did not necessarily include complete staging and lymph node dissection. Given the small number of lymph nodes removed in this cohort, meaningful interpretation of the role of lymph node involvement could not be performed; however, lymph node involvement by SBT is generally not regarded as an adverse prognostic factor, 2, 5, 6, 32, 33 and, therefore, lack of lymph node data is not likely to bias our survival analysis. 34, 35 Tumor stage was determined using the pre-2014 FIGO staging system and was based on information collected from the medical records as well as histologic slide rereview of extraovarian tissue.
Follow-up
Recurrent tumor in the form of APST was classified as "recurrence," which was classified separately from subsequent development of serous carcinoma. The cohort was linked with the Danish Pathology Data Bank until August 31, 2013. All women were followed in the Pathology Data Bank from 6 months following the primary diagnosis of SBT. All pathology records were abstracted, and all H&E slides (recurrence/subsequent serous carcinoma) were obtained for rereview, including additional comparison with slides of the primary tumor and implants from the initial surgery. The subsequent serous carcinomas were classified according to the 2014 WHO criteria. 5 We did not determine disease-specific survival because noninvasive low-grade serous tumors are often indolent and recur over the course of many years, confounding the exact cause of death. Death certificates often cite the cause of death as "ovarian cancer" even when there is no evidence to indicate that tumor is present at the time of death. Accordingly, in lieu of diseasespecific survival, subsequent development of histologically confirmed invasive serous carcinoma was used as a primary endpoint given its known poor outcome. [36] [37] [38] [39] [40] As patients with a diagnosis of a noninvasive low-grade serous tumor may have died from tumor progression or have deaths related to nonmalignant complications (such as bowel obstruction due to adhesions from implants, which is not an infrequent complication of noninvasive low-grade serous tumors), death due to any cause is also provided to establish differences in life expectancy for women with a diagnosis of APST versus niLGSC.
Statistical Analysis
The w 2 test or the Fisher exact test was used to compare categorical variables, and t test was used to compare continuous variables. Time to subsequent development of histologically confirmed invasive serous carcinoma and death from all causes, respectively, was calculated from the date of the primary ovarian tumor (APST or niLGSC). Cox proportional hazards regression analysis with time since diagnosis as the underlying time scale was used to estimate associations between type of ovarian tumor and type of implant, respectively, and development of serous carcinoma and all-cause mortality, respectively. Associations were presented as hazard ratios (HRs) and 95% confidence intervals (95% CIs). In all analyses, age was included as a continuous covariate. Statistical modeling was performed using the SAS/STAT version 8.2 (SAS Institute, Cary, NC).
RESULTS
General Clinicopathologic Features
Nine hundred forty-two women with either APST or niLGSC met inclusion criteria and were suitable for follow-up. Of these, 867 women (92%) had only APST, whereas 75 (8%) had niLGSC. Twenty-one women with niLGSC (28%) had a contralateral APST. Compared with APST, niLGSC was associated with significantly higher frequencies of bilaterality (45/ 
Histologic Features of Primary Ovarian Tumors APST
The level of tissue sampling was 1.1 (mean) blocks per centimeter of tumor (range, 0.1 to 11.3); information on sampling was missing in 26 cases. Tumors were intracystic and/or exophytic (with or without "autoimplants") and exhibited features typical of APST with hierarchical papillary branching, in which larger papillae progressively branched into smaller papillae terminating in small and detached papillary clusters (Fig. 1) . The papillae were lined by a heterogenous population consisting of cuboidal, columnar, and rounded cells with abundant eosinophilic cytoplasm. Cilia were frequently present, and nuclei were relatively bland. Psammoma bodies were occasionally present.
Forty women (5%) had a micropapillary component measuring Z1 mm but <5 mm in greatest dimension and, therefore, did not satisfy quantitative criteria for a diagnosis of niLGSC. 5 Eight hundred twenty-seven women (95%) had no micropapillary component.
Two hundred thirty-four women (27%) had tumors with architecture that was predominantly cystadenomatous/adenofibromatous, in which the APST component accounted for <50% of the tumor and that the majority of the tumor contained a serous cystadenoma/adenofibroma component (Fig. 1D ). In contrast, 73% of cases either contained no cystadenomatous/ adenofibromatous component or had a cystadenoma/ adenofibroma component that accounted for <50% of the tumor.
niLGSC
The level of tissue sampling was 1.5 (mean) blocks per centimeter of tumor (range, 0.3 to 7.7); information on sampling was missing in 3 cases. Tumors were intracystic and/or exophytic (with or without "autoimplants") and exhibited features characteristic of niLGSC (Fig. 2) . In general, niLGSC lacked the classic hierarchical papillary branching pattern of APST. Instead, large papillae frequently showed immediate transition to elongated micropapillary structures that were usually 5 times longer than wide (Medusa head appearance). Frequently, sheets of detached micropapillae were present between the larger papillae. Variable amounts of cribriform architecture were also noted (Fig. 3) . Psammoma bodies were occasionally present.
Some tumors were pure niLGSC, whereas others contained a background of APST. The proportion of any tumor containing Z5 mm of micropapillary growth in greatest dimension, as described above to qualify for a diagnosis of niLGSC, varied from case to case (70%, median; 60%, mean; range, 1% to 100%).
Eleven women (15%) had tumors with architecture that was predominantly cystadenomatous/adenofibromatous, in which the niLGSC component accounted for <50% of the tumor. In contrast, 85% of cases either contained no cystadenomatous/adenofibromatous component or had a cystadenoma/adenofibroma component that accounted for <50% of the tumor.
FIGO Stage
The stage distribution for APST was as follows: stage I in 754 women (87%), II in 54 (6%), and III in 59 women (7%). For niLGSC, the corresponding distribution was: stage I in 55 women (73%), II in 11 (15%), III in 8 (11%), and IV in 1 (1%). Presentation with advanced stage was significantly more frequent with niLGSC (Table 2) .
Implants
Among women with advanced stage APST, 104 (92%) had noninvasive implants (Fig. 4) , whereas 9 (8%) had invasive implants. For advanced stage niLGSCs, 10 (50%) had noninvasive implants and 10 (50%) women had invasive implants (Fig. 5) . niLGSC was associated with a significantly higher frequency of invasive implants (Table 2) .
Microinvasion/Microinvasive Carcinoma
Of 18 women with APST and microinvasion/microinvasive carcinoma, 10 (10/18; 56%) had only the conventional type of microinvasion (Fig. 6) , and 8 (8/18; 44%) had microinvasive carcinoma (Table 3 ). These ranged from 1 focus per case to multiple; the largest dimension of any individual focus measured <3 mm in 15 women, Z3 to <5 mm in 1 woman, and Z5 mm in 2 patients. However, neither type exhibited destructive stromal invasion. Seven women with niLGSC (7/75; 9%) contained microinvasive carcinoma (Fig. 7) , and one of these (1/7; 14%) also had microinvasion of the conventional type (Table 4) . None of these 7 women had only the conventional type of microinvasion. These ranged from 1 focus per case to multiple; the largest dimension of any individual focus measured <3 mm in 2 women, Z3 to <5 mm in 3 patients, and Z5 mm in 2 women. Of the 7 cases, 1 focus displayed an "inverted macropapillary" pattern ( Fig. 8) , and 2 had a cribriform pattern.
Among women with microinvasion/microinvasive carcinoma, microinvasion of the conventional type only was more frequent in APST compared with niLGSC ( 
Risk of Subsequent Serous Carcinoma and Death in Relation to APST Versus niLGSC
None of the women in the study were lost to follow-up, which ranged up to 36 years (median, 15 y). Forty-one women (4%) with either APST or niLGSC subsequently developed an invasive serous carcinoma, 38 of which were low grade and 3 high grade. The median time from diagnosis of APST/niLGSC to serous carcinoma was 10 years (range, 0.6 to 25 y). Serous carcinoma (Fig. 9 ) developed in 33 women (4%) with APST and 8 (11%) with niLGSC ( Table 5 ). The rate for subsequent serous carcinoma was significantly higher for niLGSC as compared with APST (HR = 3.8; 95% CI, 1.7-8.2) when adjusting for age at and time since diagnosis of APST or niLGSC.
Using all-cause mortality as another endpoint, the risk of death for women with niLGSC was not significantly different from APST after adjusting for age at and time since diagnosis of APST or niLGSC (HR = 1.2; 95% CI, 0.8-1.9) ( Table 5 ).
Risk of Subsequent Serous Carcinoma and Death in Relation to Presence and Type of Implant
In an analysis of implants regardless of type of ovarian tumor (APST or niLGSC), noninvasive implants and invasive implants were associated with statistically significantly higher rates of subsequent development of serous carcinoma compared with no implants (HR = 7.7; 95% CI, 3.9-15.0 for noninvasive versus no implants; HR = 42.3; 95% CI, 16.1-111.1 for invasive versus no implants) (Table 5 ), but this risk was higher with invasive implants. When directly comparing noninvasive versus invasive implants, invasive implants were associated with a statistically significantly higher risk for subsequent development of serous carcinoma (HR = 9.0; 95% CI, 2.5-32.7) ( Table 6 ). In addition, noninvasive and invasive implants were associated with a statistically significantly increased risk of death of any cause after adjusting for age at and time since diagnosis of APST or niLGSC: noninvasive implants versus stage I disease (HR = 1.8; 95% CI, 1.3-2.6) and invasive implants versus stage I disease (HR = 6.6; 95% CI, 3.7-11.8) ( Table 5 ).
Risk of Subsequent Serous Carcinoma and Death in Relation to APST Versus niLGSC and Presence and Type of Implant
In women with no implants, subsequent serous carcinoma developed in 13 of 754 APSTs (2%), whereas in niLGSC without implants, carcinoma developed in a higher proportion (4/55 [7%]). In contrast, in women with implants, no statistically significant differences were found between APST and niLGSC as serous carcinoma developed in 17 of 104 (16%) APSTs with noninvasive implants and in 1 of 10 (10%) niLGSCs with noninvasive implants; in APSTs with invasive implants, carcinoma developed in 3 of 9 (33%) and in 3 of 10 (30%) niLGSCs with invasive implants.
After adjusting for age at and time since diagnosis of APST or niLGSC among women without implants, those with niLGSC had a significantly increased risk of (Table 6 ). However, no difference in the risk of death from all causes was observed (HR = 1.1; 95% CI, 0.7-1.8) (Table 6 ). In contrast, among women with implants, the risk of subsequent serous carcinoma was not significantly related to APST versus niLGSC when adjusting for age at and time since diagnosis of APST or niLGSC and type of implant (Table 6 ). This difference also was not statistically significant with further adjustment for microinvasive carcinoma (HR = 0.5; 95% CI, 0.1-2.5) ( Table 6 ). In contrast, the type of implant was a significant predictor of serous carcinoma after adjusting for age at and time since diagnosis and type of ovarian tumor (APST vs. niLGSC) (HR = 9.0; 95% CI, 2.5-32.7). Even after adjusting for microinvasive carcinoma, this difference was statistically significant (HR = 6.9; 95% CI, 1.6-30.5) ( Table 6 ). A similar pattern was seen for risk of death from all causes, although less pronounced (Table 6 ).
DISCUSSION
We have previously analyzed our total cohort with regard to the risk of subsequent serous carcinoma and identified risk factors for recurrence and progression. 41 In the present long-term population-based study, we show that APSTs/niLGSCs are very indolent and that the risk of developing subsequent serous carcinoma is significantly higher among women with stage I niLGSCs compared with APSTs (Tables 5 and 6 ). Even when controlling for surface involvement (ie, stage IC) in this cohort, this higher risk with niLGSC among stage I cases was still statistically significant. 41 However, the overall risk of death (all-cause mortality) is similar for APST and niLGSC among either stage I or >I cases (Table 6) suggesting that other factors, apart from the development of carcinoma, can result in a fatal outcome (eg, small bowel obstruction from adhesions due to noninvasive implants, etc.). These findings have not been observed in previous studies. 3, 10, 26, [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] However, interpreting data from other outcome-based studies is complicated by multiple factors. These include variation in surgical treatment (conservative/fertility-sparing surgery vs. variable degrees of completeness of surgical staging), lack of a uniform pathology review, differing criteria for invasive implants, small number of cases, selection bias, insufficient duration of follow-up, losses to follow-up, and that person-years at risk may not have been taken into account when comparing APSTs and niLGSCs. Another interesting finding in this study was that whereas stage I niLGSCs had a significantly higher risk for subsequent serous carcinoma compared with stage I APSTs, there was no difference in this risk between ad-FIGURE 7. Microinvasive carcinoma. Micropapillae in clear lacunar spaces within stroma. Note the relative uniform population of cells with rounded nuclei, many of which contain a small prominent nucleolus, and the higher nuclear:cytoplasmic ratio compared with the conventional type of microinvasion as shown in Figure 6 . 41 Thus, in the setting of advanced stage disease, the presence of implants (even noninvasive) is such an important driver of behavior that the histologic type of ovarian tumor loses significance.
In our study, 21% of cases submitted to the pathology panel as SBTs were disqualified, most often because they were serous cystadenomas/adenofibromas with slight epithelial proliferation that represented <10% of the neoplasm. A smaller proportion were carcinomas of various types. Although architectural/quantitative features allow for distinction between APST and niLGSC, it is important to acknowledge cytologic differences between both tumors as the diagnosis of niLGSC can be erroneous if attention is not directed to cytologic features but is based solely on the presence of a micropapillary pattern. Specifically, APSTs can exhibit focal micropapillary areas but are otherwise composed of a heterogenous population of cells consisting of cuboidal, columnar, and rounded cells with abundant eosinophilic cytoplasm. Cilia are frequently present, and nuclei are relatively bland. In contrast, the cells in niLGSC are relatively uniform in appearance and lack eosinophilic cytoplasm and cilia. There is a higher nuclear:cytoplasmic ratio, the nuclear chromatin is coarser, and nuclei frequently contain a small but prominent nucleolus. The cells are virtually identical to those in invasive LGSC. Therefore, examination of areas of micropapillary architecture on high-power magnification can allow for the cytologic features to help further refine the distinction between APST and niLGSC, although occasionally there can be some cytologic overlap between these tumors.
Criteria for classification of implants have been controversial. 2 The traditional criteria for the diagnosis of invasive implants require infiltration of underlying tissue, 1 but in this study we used expanded criteria, which in addition to infiltration of underlying tissue, include exophytic or endophytic micropapillary architecture resembling niLGSC or solid nests surrounded by a clear space. 3 Previously, a study by Bell et al 3 demonstrated that the expanded criteria were associated with poor outcome. However, in a recent study by McKenney et al, 56 invasive implants diagnosed by expanded criteria without classic destructive stromal invasion (ie, micropapillary architecture or solid nests surrounded by cleft-like spaces) were found to be often associated with tissue invasion but did not add significant prognostic value beyond classic invasion alone. In that study, the median follow-up for the entire cohort of advanced stage SBTs was 7.8 years, and 26% of women with invasive implants having only classic destructive stromal invasion and 23% of women with invasive implants having only micropapillary architecture or solid nests surrounded by cleft-like spaces were lost to follow-up, respectively.
Nonetheless, as we found that invasive implants, as defined in this study, were associated with higher risks of both subsequent serous carcinoma and all-cause mortality (Table 6 ), this supports the use of the expanded criteria and that the WHO recommendation that invasive implants be termed "LGSC" 5 is valid. A detailed analysis of both traditional and expanded criteria for invasive implants in this cohort, including correlation with KRAS/ BRAF genotype for potential prediction of malignant potential of noninvasive and invasive implants, will be the subject of a forthcoming study.
Previously, it has been suggested that advanced stage niLGSC is not an independent adverse prognostic factor when controlling for implant type, 47 a finding also observed in our study. Specifically, a few studies have demonstrated that niLGSC compared with APST have a significantly poorer progression-free or disease-specific survival with univariate analysis but that this difference was not statistically significant upon multivariate analysis. 42, 47, 50 Adjusting for implant type in niLGSCs in the setting of multivariate analysis is problematic given that invasive implants and niLGSC covary with one another and that essentially all studies on advanced stage niLGSC with follow-up are limited by relatively small numbers of such cases. 10, 26, 42, 43, [45] [46] [47] [48] [49] 52, 53, 55 Thus, subdividing small numbers of patients with advanced stage niLGSCs into smaller groups with noninvasive and invasive implants, respectively, yields very low numbers. In addition, such a survival analysis between APST and niLGSC with stratification according to implant type ideally should take into account differences in age and length of follow-up between groups. To achieve sufficient statistical power, a large number of advanced stage niLGSCs is required. Even in our large series, only 20 niLGSCs were of advanced stage as the frequency of this tumor in the population is low (8% in our series) and that even advanced stage noninvasive low-grade serous tumors (APST and niLGSC combined) in a population-based setting are uncommon (14% in our series). Our findings, however, in conjunction with a number of prior studies, clearly show that niLGSC is significantly associated with invasive implants, which is a known poor prognostic factor. 3, 10, 42, 43, [45] [46] [47] [48] [49] 52, 53, 55 Another controversial and confusing feature is "microinvasion." 2 Much of the literature has shown that microinvasion is not an adverse prognostic factor. 2, 5, 6 However, some studies suggest that microinvasion may covary with other adverse prognostic factors such as invasive implants, advanced stage, unresectable disease, and micropapillary architecture in the SBT. 31 Indeed, in the 2014 WHO Classification for Gynecologic Tumors, 2 types of "microinvasion" are described. 5 The more common pattern is the conventional type, which is composed of single cells and small clusters of cells with abundant eosinophilic cytoplasm within the stroma of the papillae.
The less common type is one with micropapillary-rich architecture and cells resembling LGSC and is designated "microinvasive carcinoma." Given that the majority of the literature shows that the conventional type of microinvasion is not an adverse prognostic factor, as well as immunohistochemical studies showing that the constituent cells exhibit features of terminal differentiation and senescence, 57 it has been proposed that microinvasion does not play a role in the pathogenesis of tumor progression. In contrast, it has been suspected that "microinvasive carcinoma" may represent an early form of invasive LGSC. In this study, microinvasive carcinoma did not have any prognostic effect (development of subsequent serous carcinoma) after adjusting for type of ovarian tumor (APST vs. niLGSC) and implant type. Nevertheless, the finding that microinvasive carcinoma was much more common in niLGSC, whereas microinvasion of the conventional type occurred more frequently with APST, provides support that microinvasive carcinoma may represent an early form of invasive LGSC.
A potential limitation of the current study is that disease-specific survival is not available for reasons detailed in the Materials and Methods section. However, when mortality for APST versus niLGSC was compared, there was no significant difference in the risk for death from any cause despite the greater risk of developing carcinoma among women with niLGSC. We were unable to determine the exact cause of death in this study, but it is likely that the cohort of women with niLGSCs experienced a higher fraction of tumor-related deaths, whereas the cohort with APSTs had a greater proportion of nontumor-related deaths. This is an important finding as the management of benign complications will be very different from those that are cancer related.
However, in our prior epidemiologic studies of this cohort, there are some important observations worth noting with regard to the natural history of noninvasive low-grade serous tumors: stage I APSTs had no difference in overall survival (all-cause mortality) compared with the background general population, 30 the risk of subsequent serous carcinoma in women with stage I APSTs was low (2%), stage I APSTs showed a significantly higher risk for subsequent serous carcinoma compared with the background general population, and this risk for APSTs (all stages combined) significantly increased over 20 years. 41 In the current study, serous carcinomas developing after a diagnosis of either APST or niLGSC (all stages) occurred up to 25 years later. In a study of advanced stage SBTs with noninvasive implants by Silva et al, 58 survival of this subset of noninvasive low-grade serous tumors was time dependent. On the basis of the findings from the current study and our prior ones using this same cohort, we, therefore, agree with the recommendations of Silva et al 58 that 20 years of follow-up is necessary to fully assess the behavior of noninvasive lowgrade serous tumors, even for stage I APSTs.
In conclusion, this long-term, population-based study of noninvasive low-grade serous tumors involving the entire female population of Denmark showed that the risk of subsequent serous carcinoma was significantly higher with niLGSC compared with APST among patients with stage I disease. Nonetheless, the mortality from all causes is not different between APST and niLGSC among either stage I or >I cases. In addition, although the presence of invasive implants is the single most adverse prognostic factor, subclassification into APST and niLGSC is important as it stratifies women with respect to risk for advanced stage disease and invasive implants among all women and subsequent development of serous carcinoma among stage I cases. Lastly, it is important to emphasize that even though invasive implants carry the highest risk for subsequent serous carcinoma and all-cause mortality, noninvasive implants are also associated with a statistically significantly increased risk, albeit not nearly as high as with invasive implants.
